Interview 26 Oct 2017 Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much to show for themselves besides Amgen’s Imlygic, but PsiOxus, one of our top Oxford biotechs, has some ideas to make them bear fruit. The company […] October 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 British Researchers Develop Clever Nanoparticles to Kill Cancer Cells The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […] October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 British Scientists Prove that it Takes Very Few Mutations to Cause Cancer Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 Swiss Biotech Rakes in $200M to Accelerate Antibody-based Cancer Treatments ADC Therapeutics has received massive private funding to progress two of its lead candidates for cancer through clinical trials. ADC Therapeutics, based in Lausanne, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for the treatment of cancer. The technology uses the specificity of antibodies to deliver a therapeutic agent to target cells only. The biotech has […] October 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2017 The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and pharma. In 1998, after 10 years working with big pharma, she founded her first company, Bootcamp, to help young professionals […] October 23, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2017 Leading Pharma-Academic Partnership Unravels the Mystery of a Major Cancer Gene The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve our understanding of how this happens. The Babraham Institute, Cambridge, UK and AstraZeneca have unveiled research that helps us to better understand a key cancer gene, PTEN – reportedly the second most altered gene in cancers. […] October 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […] October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’ Gilead’s CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis’ CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T therapy to be approved in the US. The FDA has authorized its use to treat aggressive B-cell non-Hodgkin lymphoma in patients for whom at least two […] October 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines CureVac will be working with pharma giant Eli Lilly in the development of up to five cancer vaccines based on mRNA technology. Eli Lilly will pay CureVac $50M (€43M) upfront and invest €45M in equity to kick off a collaboration for the development and commercialization of up to five mRNA vaccines for cancer. CureVac could receive up […] October 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 German Researchers Set the Immune System Free to Fight Against Cancer There could be a way to stop cancers escaping from the immune system, and researchers hope to use this for more effective cancer treatments. Researchers at Universität Bonn have found a way to “release the brakes” in the immune system that helps cancers to survive. Cancers benefit from this by pretending to be regular cells, […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data OncoDNA is gathering prestigious oncology centers to take part in Moncodaneum, an international project to bring precision medicine to cancer patients. The Belgian biotech OncoDNA has announced that it will be collaborating with the Strasbourg University Hospital, France, and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer. The two […] October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 18 Oct 2017 Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer? Everything you need to know about CAR-T, a revolutionary cell therapy for cancer. You might have heard of CAR-T cell therapy as a “miracle cure” for cancer. The approval of Novartis’ Kymriah, the first CAR-T therapy, made headlines in August as it was the first gene-edited cell therapy for cancer to make it to the […] October 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email